Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best way to give nilotinib when given
alone or sequentially after imatinib mesylate after donor stem cell transplant in treating
patients with acute lymphoblastic leukemia or chronic myelogenous leukemia. Nilotinib and
imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth.